5-methyl-4-(N-cyclopropylmethyl-N-acetamido)isoxazole | 600699-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methyl-4-(N-cyclopropylmethyl-N-acetamido)isoxazole
• 英文别名: N-(cyclopropylmethyl)-N-(5-methyl-1,2-oxazol-4-yl)acetamide
• CAS: 600699-40-9
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.233
• InChiKey: QCIIHVJFOQRNAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  46.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methyl-4-(N-cyclopropylmethyl-N-acetamido)isoxazole 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

  摘要：

  The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was pro. led in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.075
• 作为产物：
  描述：

  5-methyl-4-(N-cyclopropylmethylamino)isoxazole 、 乙酸酐 在 sodium acetate 作用下， 以 溶剂黄146 为溶剂， 生成 5-methyl-4-(N-cyclopropylmethyl-N-acetamido)isoxazole
  参考文献：
  名称：

  Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

  摘要：

  The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was pro. led in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.075

文献信息

• PYRIMIDINE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1485375B1

  公开（公告）日：2009-06-17